BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as its Chief Medical Officer.
Click here to view original post
News
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Raul […]
News
Colorado poised to become second state with legalized ‘medicinal psychedelics’
Colorado looks set to legalize magic mushrooms in this week’s midterm elections, with the group opposing the ballot question conceding defeat. As of Thursday afternoon, Proposition 122 was passing with 51.4% of the vote, though […]
News
Early data for Avidity’s RNA therapy show possible functional benefit in muscular dystrophy
Avidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to functional improvement among people with facioscapulohumeral muscular dystrophy (FSHD) in a phase 1/2 trial. The initial data drop assesses del-brax, […]
